Navigation Links
Commencement of GMP Production Project for Lead Anti-Cancer Product PAT-LM1
Date:6/2/2011

MELBOURNE, Australia and PRINCETON, N.J., June 2, 2011 /PRNewswire/ -- Patrys Limited (ASX: PAB) (the "Company"), a biopharmaceutical company focused on the development of novel treatments for cancer, is pleased to announce it has extended its relationship with Laureate Biopharmaceutical Services, Inc. ("Laureate"), to manufacture lead product PAT-LM1 for preclinical and clinical use.  

PAT-LM1 is a natural human antibody that has been shown to have anti-cancer properties, in multiple animal models, including a potent effect in models of pancreatic, lung and colon cancers.  

Laureate is a US based full-service biopharmaceutical contract development and manufacturing organization and has extensive experience in the production of both clinical and marketed products in the biotechnology sector.  

Patrys has an existing arrangement with Laureate for the production of another lead anti-cancer product PAT-SM6.  The PAT-SM6 project at Laureate has been very successful with production yields far exceeding expectations.  PAT-SM6 is currently being evaluated in a human clinical trial targeting patients with melanoma.  

"Laureate has extensive antibody production experience and given the success with PAT-SM6 production, which is very similar to what will be needed for PAT-LM1, Patrys is confident that Laureate can produce yields of PAT-LM1 sufficient to support commercialisation," said Mike Conner, Patrys Vice President, Manufacturing.

Michael A. Griffith, Chief Executive Officer of Laureate Biopharmaceutical Services, Inc added, "We are pleased to be Patrys' chosen manufacturing partner, giving Laureate the opportunity to share in the advancement of their novel anti-cancer products through clinical development."

"From what we have experienced first-hand with the successful production of PAT-SM6, the Patrys' production platform for its natural human antibodies is robust and productive. We expect that this platform will be very competitive in the field of antibody production."

Patrys CEO Dan Devine added that securing the manufacturing for PAT-LM1 was an important milestone toward evaluating PAT-LM1 in a first-in-human clinical trial in 2012.

The PAT-LM1 project has recently commenced at Laureate.

For further information, please contact:Patrys Limited:

Patrys IR:

Patrys Media:Daniel Devine

Rebecca Wilson

Tom DonovanChief Executive Officer

Buchan Consulting

Buchan ConsultingP: +61 3 9670 3273  

P: 0417 382 391

P: +61 3 9866 4722info@patrys.com

rwilson@bcg.com.au

tdonovan@bcg.com.auAbout Patrys Limited:Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of natural human antibodies as therapies for cancer and other major diseases.  Patrys has a deep pipeline of anti-cancer natural human antibodies that enable both internal development and partnering opportunities.  More information can be found at www.patrys.com.

About PAT-LM1:PAT-LM1 is a natural human antibody that has been shown to have potent anti-cancer properties in a large number of laboratory and animal studies.  This lead product binds to a proprietary disease target that is expressed on the surface of cancer cells, but not on the surface of the healthy tissues screened.  With over 200 individual patient tumours screened, covering several different cancers, PAT-LM1 binds to nearly 98% of those tumours regardless of cancer type, age, gender or disease stage.  Patrys has filed patent applications to cover the PAT-LM1 molecule and its disease target.  

About PAT-SM6: The natural human antibody PAT-SM6 has been shown to have potent anti-cancer properties in a large number of laboratory and animal studies. More specifically, Patrys has now screened PAT-SM6 against more than 200 tumours from individual patients with various cancers, and the product binds to over 90% of the tumours screened regardless of cancer type or patient age, gender or disease stage. With respect to melanoma, PAT-SM6 has shown particularly strong promise. Patrys has filed patent applications to cover the PAT-SM6 antibody molecule, disease target, and the mechanism of action.

About Laureate Biopharmaceutical Services, Inc.Laureate Biopharmaceutical Services, Inc. is a full-service biopharmaceutical contract development and manufacturing organization. Laureate Biopharma's scientists are expert in process development and cGMP production of therapeutic proteins including monoclonal antibodies and Fc-fusion proteins. In addition, the company's portfolio of services includes aseptic filling, cell line development, analytical and stability testing, and regulatory support. Laureate Biopharma has served a global client base from its Princeton, New Jersey facility since 1981 and is a portfolio company of Saints Capital, LLC. For more information, please visit www.LBioS.com.


'/>"/>

SOURCE Laureate Biopharmaceutical Services, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Marinus Pharmaceuticals Announces Commencement of Phase 2 Trial of Ganaxolone for the Treatment of Posttraumatic Stress Disorder
2. Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical
3. Vanda Pharmaceuticals Announces Commencement of Clinical Study of Long-Acting Injectable Formulation of Fanapt®
4. Watson Announces Commencement of Secondary Offering by Selling Stockholder
5. Commencement of a Phase II Clinical Trial of SG2000 in Ovarian Cancer
6. Cogdell Spencer Announces Commencement of Common Stock Offering
7. U.S. Surgeon General Dr. Regina M. Benjamin to Deliver Commencement Address at Albany College of Pharmacy and Health Sciences
8. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
9. FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
10. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
11. TPI Receives Production License for Its Anti-diabetic Drug Gliclazide Tablets from Chinas SFDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... BERLIN , April 29, 2016 ... world-leading glyco-biology expertise, today announces the appointment of Dr. ... Dr. Zurlo is an oncologist with many years ... pharmaceutical and biotechnology industries. His last role was at ... Member of the Executive Board. Previously Dr. Zurlo held ...
(Date:4/28/2016)... , April 28, 2016 Research ... "Global Plastic Surgery Products Market 2016-2020" report to ... ) , The global plastic surgery products ... 9.47% during the period 2016-2020. , ,The growing adoption ... to the growth of the market. Lasers are used ...
(Date:4/28/2016)... NEW YORK , April 28, 2016 ... of online consumer insights on healthcare, announced today that ... in their report Cool Vendor in Life Sciences, ... , April 15, 2016.  The report focuses on life-science- ... to gain insight from patients and doctors, confirm medication ...
Breaking Medicine Technology:
(Date:4/30/2016)... ... April 30, 2016 , ... Orlando-based Maximized Living has selected Dr. ... gold in Rio. Under the care of Maximized Living doctors at the London ... unprecedented showing, Maximized Living is sending the largest contingent of elite chiropractors to Rio ...
(Date:4/29/2016)... ... April 29, 2016 , ... In an article published ... her enthusiasm for Botox and lip injections, which she underwent in order to feel ... Valley Music and Arts Festival. The article explains that Ms. Mirmelli’s situation is not ...
(Date:4/29/2016)... ... April 29, 2016 , ... Shamangelic ... the addition Onnit brand Alpha BRAIN and New Mood Daily-Stress Formula for brain ... mood optimization products to the store is just one more way Shamangelic Healing ...
(Date:4/29/2016)... ... April 29, 2016 , ... The ... nation’s productivity, stability, even security. Most importantly, employees are the single most important ... are American workers so unhappy? , Just under half of American workers are ...
(Date:4/29/2016)... ... 29, 2016 , ... Conditions were ideal for Global Lyme Alliance’s (GLA) 2nd ... sunny skies, a light breeze and temperatures in the 60s. Over 400 runners, walkers ... and Walk and 1-mile walk were held to increase awareness about Lyme disease ...
Breaking Medicine News(10 mins):